Clinical trials: Solid Tumor, completed
Adult Solid Neoplasm
Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
This phase I trial is studying the side effects and best dose of belinostat when given together with isotretinoin in treating patients with metastatic or unresectable solid tumors.
- Trial name
- NCT00334789
- Testing
- Belinostat, Isotretinoin, Pharmacological Study
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Cancer
C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors
This is an open-label study being conducted to determine the metabolism and physiological disposition of radiolabeled LY2603618 after a single dose in patients with advanced and/or metastatic solid tumors.
- Trial name
- NCT01296568
- Testing
- LY2603618, Pemetrexed, Gemcitabine
- Where
- Switzerland
- Volunteers
- 3 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer, Renal Cell Carcinoma
Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)
This pilot study will aim to determine whether circulating tumor cells (CTCs) can be captured using the novel cMET based ferrofluid.
- Conditions
- Prostate Cancer, Renal Cell Carcinoma, Bladder Cancer, Colorectal Cancer
- Trial name
- NCT02080650
- Testing
- Mesenchymal-marker based ferrofluid (c-MET), Epithelial cell adhesion molecule (EpCAM) ferrofluid
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Duke University
Gastric Cancer, Bladder Cancer
Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies
The purpose of the study is to determine to evaluate safety and tolerability of CPL304110 when administered once daily to adults with advanced solid malignancies.
- Conditions
- Gastric Cancer, Bladder Cancer, Squamous Non-small Cell Lung Cancer, Cholangiocarcinoma
- Trial name
- NCT04149691
- Testing
- CPL304110
- Where
- 7 sites in Poland
- Volunteers
- 37 people
- Sponsor
- Celon Pharma SA
Tumors, Solid Malignant Tumors
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
This is a phase 1/2 study evaluating safety, tolerability, and efficacy of lenvatinib as single-agent, and in combination with chemotherapy (ifosfamide and etoposide) in children and adolescents with refractory or relapsed solid…
- Conditions
- Tumors, Solid Malignant Tumors, Osteosarcoma, Differentiated Thyroid Cancer (DTC)
- Trial name
- NCT02432274
- Testing
- Lenvatinib, Ifosfamide, Etoposide
- Where
- 19 sites in United States, France and 4 more
- Volunteers
- 117 people
- Sponsor
- Eisai Limited
Bone Metastases
Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors
A multi-center, randomized, double-blind, parallel controlled Phase III clinical study to evaluate the clinical efficacy and safety of MW032 and Xgeva® in patients with bone metastases from solid tumors.
- Trial name
- NCT04812509
- Testing
- MW032, Xgeva
- Where
- China
- Volunteers
- 708 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Virtual Reality Experiences for Anxiety and Pain Control
This trial studies the impact of virtual reality experiences on anxiety before surgery and pain after surgery. The goal of this study is to examine how different virtual reality experiences may help reduce anxiety and improve…
- Trial name
- NCT04759183
- Testing
- Survey Administration, Virtual Reality Game, Virtual Reality Meditation
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- OHSU Knight Cancer Institute
Advanced Solid Tumors, Metastatic Breast Cancer
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
Study has two parts: 1. Dose-finding: to determine the maximum tolerated dose (MTD) and to evaluate the safety and tolerability of RAD001 (everolimus , Afinitor®) in combination with BEZ235 in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma
- Trial name
- NCT01482156
- Testing
- RAD001 + BEZ235
- Where
- 10 sites in United States, Belgium and 5 more
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
Malignancy, Metastasis
Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors
Participants in this single-center, open-label, dose-escalation, Phase 1 study will initially receive intravenous (IV) olaratumab once every 2 weeks or on Days 1 and 8 every 3 weeks for 6 weeks (one cycle).
- Trial name
- NCT01199822
- Testing
- Olaratumab
- Where
- Japan
- Volunteers
- 16 people
- Sponsor
- Eli Lilly and Company
Solid Tumor, Adult
Study of ASTX029 in Subjects With Advanced Solid Tumors
This study is a first-in-human, open-label, multicenter, Phase 1-2 study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ASTX029 administered orally to participants with advanced…
- Trial name
- NCT03520075
- Testing
- ASTX029
- Where
- 31 sites in United States, France and 2 more
- Volunteers
- 192 people
- Sponsor
- Taiho Oncology, Inc.
Cancer
A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function
This is a Phase Ib, open-label, multiple-center, multiple-dose study designed to evaluate the pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies (including hepatocellular carcinoma and…
- Trial name
- NCT01546519
- Testing
- Vismodegib
- Where
- 5 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Pancreas Cancer, Ovarian Cancer
Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy
This is a single arm, single-stage, phase II trial to evaluate the activity of Regorafenib in patients with metastatic solid tumors (pancreatic cancer, ovarian cancer, melanoma, sarcoma, thymoma (type B2 - B3) and thymic…
- Conditions
- Pancreas Cancer, Ovarian Cancer, Melanoma, Sarcoma
- Trial name
- RESOUND (NCT02307500)
- Testing
- Regorafenib
- Where
- Italy
- Volunteers
- 82 people
- Sponsor
- Istituto Clinico Humanitas
Tumor, Cancer
Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer
Patients with metastatic cancer are generally treated with chemotherapy, which has improved median survival compared to best supportive care.
- Conditions
- Tumor, Cancer, Melanoma, Sarcoma
- Trial name
- NCT01215500
- Testing
- Hypofractionated RT
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of Chicago
Breast Cancer, Colorectal Cancer
Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid Tumors
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Conditions
- Breast Cancer, Colorectal Cancer, Pancreatic Cancer
- Trial name
- NCT00369109
- Testing
- biologic sample preservation procedure, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Solid Tumor
A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin
AB-106-C111 is China-only study, for investigating the drug interaction between AB-106 and P-gp substrate (Digoxin). （n=16）
- Trial name
- NCT05357911
- Testing
- AB-106, digoxin
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Nuvation Bio Inc.
HER2-Positive Solid Tumors
A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of different doses of M802 in patients with HER2-positive advanced solid tumors, and to determine the dose limiting toxicity (DLT) and the maximum tolerated…
- Trial name
- NCT04501770
- Testing
- Chort 1 of M802, Chort 2 of M802, Cohort 3 of M802
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
Lymphoma, Small Intestine Cancer
VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have advanced solid…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00025129
- Testing
- laromustine
- Where
- 3 sites in United States
- Sponsor
- Vion Pharmaceuticals
Solid Tumors
Effect of Ketoconazole Inhibition of CYP3A on Urinary Excretion of Docetaxel
Primary Objective: To confirm if ketoconazole inhibition of CYP3A activity affects fractional excretion of docetaxel in the urine.
- Trial name
- NCT00697437
- Testing
- Docetaxel, Ketoconazole
- Where
- Singapore
- Volunteers
- 10 people
- Sponsor
- National University Hospital, Singapore
Solid Tumor
GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies
The primary objective of the study is to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and pharmacokinetics (PK) of acasunlimab (also known as GEN1046) administered as monotherapy or in combination with…
- Trial name
- NCT04937153
- Testing
- Acasunlimab, Pembrolizumab
- Where
- 2 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Genmab
Advanced Solid Tumors
A Phase I Study of LEE011 in Asian Patients
This study will evaluate safety and tolerability to estimate the MTD and/or recommended dose for expansion.
- Trial name
- NCT01898845
- Testing
- LEE011
- Where
- 2 sites in Japan
- Volunteers
- 17 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.